Evidence map›Paper›PMID 30704900›Full record

ArticleMolecular cell2019

BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation.

Dali Zong, Salomé Adam, Yifan Wang, Hiroyuki Sasanuma, Elsa Callén, Matilde Murga, Amanda Day, Michael J Kruhlak, Nancy Wong, Meagan Munro and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 113 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. eLife · 2024
    Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 5 countries.

Dali ZongLaboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Salomé AdamThe Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
Yifan WangMolecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Hiroyuki SasanumaDepartment of Radiation Genetics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Elsa CallénLaboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Matilde MurgaGenomic Instability Group, Spanish National Cancer Research Center, CNIO, Madrid, Spain.
Amanda DayLaboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Michael J KruhlakLaboratory of Cancer Biology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA.
Nancy WongLaboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Meagan MunroThe Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
Arnab Ray ChaudhuriLaboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA; Department of Molecular Genetics, Erasmus University Medical Center, Rotterdam, the Netherlands.
Baktiar KarimPathology/Histotechnology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Bing XiaDepartment of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Shunichi TakedaDepartment of Radiation Genetics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Neil JohnsonMolecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Daniel DurocherThe Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
André NussenzweigLaboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA. Electronic address: andre_nussenzweig@nih.gov.
National Human Genome Research Institute · USMount Sinai Hospital · CAFox Chase Cancer Center · USKyoto University · JPErasmus MC · NLFrederick National Laboratory for Cancer Research · USNational Cancer Institute · USRutgers, The State University of New Jersey · USSpanish National Cancer Research Centre · ES

Funding

Relationship between DNA damage detection and signalingZIABC010959 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI NUSSENZWEIG, ANDRE A. · 2009 to 2025
$27.0M
Compensatory Mechanisms that Promote Homologous Recombination in BRCA1 Mutant CancersR01CA214799 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Neil Johnson · 2017 to 2026
$4.3M
DNA REPAIRZ01BC010283 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI NUSSENZWEIG, ANDRE A. · 1998 to 2008
$2.9M
Dissecting BRCA1-PALB2 Activity in DNA Repair and DevelopmentR01GM135293 · NIGMS · RESEARCH INST OF FOX CHASE CAN CTR · PI JOHNSON, NEIL · 2020 to 2023
$1.9M
Intramural NIH HHS Z01 BC010283NCI NIH HHS R01 CA214799NIGMS NIH HHS R01 GM135293
6 · The paper itself

Abstract

BRCA1 functions at two distinct steps during homologous recombination (HR). Initially, it promotes DNA end resection, and subsequently it recruits the PALB2 and BRCA2 mediator complex, which stabilizes RAD51-DNA nucleoprotein filaments. Loss of 53BP1 rescues the HR defect in BRCA1-deficient cells by increasing resection, suggesting that BRCA1's downstream role in RAD51 loading is dispensable when 53BP1 is absent. Here we show that the E3 ubiquitin ligase RNF168, in addition to its canonical role in inhibiting end resection, acts in a redundant manner with BRCA1 to load PALB2 onto damaged DNA. Loss of RNF168 negates the synthetic rescue of BRCA1 deficiency by 53BP1 deletion, and it predisposes BRCA1 heterozygous mice to cancer. BRCA1

Indexed as

HaploinsufficiencyUbiquitinationAnimalsBRCA1 ProteinBRCA2 ProteinCell Line, TumorChromatinDNA DamageFanconi Anemia Complementation Group N ProteinFemaleFibroblastsMiceMice, Inbred C57BLMice, KnockoutMutationNeoplasmsBRCA1 ProteinBRCA1 protein, humanBrca1 protein, mouseBRCA2 ProteinBRCA2 protein, mouseChromatinFanconi Anemia Complementation Group N ProteinPALB2 protein, humanPalb2 protein, mousePoly(ADP-ribose) Polymerase InhibitorsRAD51 protein, humanRad51 protein, mouseRad51 RecombinaseRNF168 protein, humanRNF168 protein, mouseTP53BP1 protein, humanTrp53bp1 protein, mouseTumor Suppressor p53-Binding Protein 1Ubiquitin-Protein LigasesBRCA1cancerchromatin ubiquitylationgenome stabilityhaploinsufficiencyhomologous recombinationPALB2RAD51replication fork protectionresectionRNF168

Identifiers

PMID30704900
PMCPMC6430682
OpenAlexW2911246008

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.